David DeNardo, PhD

David DeNardo, PhD

Primary Academic Title

Professor of Medicine, Division of Oncology, Section of Molecular Oncology, Washington University School of Medicine

Research Interest

Identifying the molecular mechanisms by which malignant cells derail anti-tumor immune responses to instead favor immune programs that facilitate tumor progression to metastasis. Understanding the immune microenvironment in which tumor cells reside will allow for the identification of pharmacological targets that can be exploited to destroy malignant disease.

Education

  • 2005: PhD, molecular cell biology, Baylor College of Medicine, Houston

Training

  • 2006 - 2010: Postdoctoral fellow, cancer immunology, University of California, San Francisco

Selected Research Publications

Chemotherapy-induced adipo-lineage cell senescence drives bone loss.
  • Raut GK, Malachowski T, Melam A, [...] DeNardo DG, Stewart SA
  • Nat Commun 2025
Neoadjuvant BMS-813160, Nivolumab, Gemcitabine, and Nab-Paclitaxel for Patients with Pancreatic Cancer.
  • Grierson PM, Wolf C, Suresh R, [...] DeNardo DG, Lim KH
  • Clin Cancer Res 2025
Human interpretable grammar encodes multicellular systems biology models to democratize virtual cell laboratories.
  • Johnson JAI, Bergman DR, Rocha HL, [...] DeNardo DG, [...] Macklin P
  • Cell 2025
Combined Flt3L and CD40 agonism restores dendritic cell-driven T cell immunity in pancreatic cancer.
  • Hogg GD, Weinstein AG, Kingston NL, [...] DeNardo DG
  • Sci Immunol 2025
HMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal Adenocarcinoma.
  • Yamamoto N, Dobersch S, Loveless I, [...] DeNardo DG, [...] Kugel S
  • Clin Cancer Res 2025
Targeting dendritic cells to drive PDAC immunotherapy response.
  • Weinstein AG, DeNardo DG
  • Trends Pharmacol Sci 2024
Senescent CAFs Mediate Immunosuppression and Drive Breast Cancer Progression.
  • Ye J, Baer JM, Faget DV, [...] DeNardo DG, Stewart SA
  • Cancer Discov 2024
Combined KRAS-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic cancer.
  • Bulle A, Liu P, Seehra K, [...] DeNardo DG, [...] Lim KH
  • Nat Commun 2024
"RIPping" off Pancreas Cancer's Blockage of Immune Surveillance.
  • Liu X, Sells BE, DeNardo DG
  • Cancer Discov 2024
Epigenetic regulation during cancer transitions across 11 tumour types.
  • Terekhanova NV, Karpova A, Liang WW, [...] DeNardo DG, [...] Ding L
  • Nature 2023

View All Publications